Why Genentech prides itself on taking a scientific approach to Business Development




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Why Genentech prides itself on taking a scientific approach to Business Development
Released on: May 16, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    One thing that differentiates the partnering group at Genentech is that 70% of their Business Development people are scientists and physicians.
  • Summary
  • Transcript
  • Participants
  • Company
One thing that differentiates the partnering group at Genentech is that 70% of their Business Development people are scientists and physicians. Tom Zioncheck, Senior Director to Genentech, discusses the benefits a solid scientific understanding can bring to partnering.
One thing that differentiates the partnering group at Genentech is that 70% of their Business Development people are scientists and physicians. Tom Zioncheck, Senior Director to Genentech, discusses the benefits a solid scientific understanding can bring to partnering.
Dr. Tom Zioncheck is a Senior Director in Business Development at Genentech. He is responsible for sourcing and in-licensing opportunities in the areas of Ophthalmology, Neuroscience, Cardiovascular and Metabolic Disease. Tom started his career at Genentech as a Postdoctoral Fellow in 1988. He was hired as a Genentech Scientist and was subsequently promoted into roles of increasing responsibility including Senior Scientist and Project Team Leader. He has made numerous drug development contributions, co-authored 30 scientific papers, is co-inventor of 6 patents, and has received multiple Genentech recognition awards. Dr. Zioncheck has served as Chair for the American Association of Pharmaceutical Scientists (AAPS) Biotech Section and is currently an Adjunct Professor in the School of Pharmacy and Health Sciences, University of the Pacific. Dr. Zioncheck earned his BS degree in Chemistry from the State University of New York at Oneonta and his PhD in Biochemistry from Purdue University.
Genentech
Genentech Inc., a portmanteau of Genetic Engineering Technology, Inc., is a biotechnology corporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer.